Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: April Update

Performance overview
Value at beginning of month: $147,509.10
Value at end of month: $158,649.70
Month over month change: +7.55%
Total IRR: 43.08%

Related indices, monthly change
NASDAQ: +0.80%
IVV (iShares Core S&P 500): +1.14%
IBB (iShares NASDAQ Biotechnology Index): -1.06%
MXI (iShares Global Materials): +2.29%
VEGI (iShares MSCI Global Agriculture Producers): +0.73%
ICLN (iShares Clean Energy): +4.20%

Individual performances


Avexis almost doubled in share price after Novartis agreed to an acquisition. Synlogic also had an excellent first month in the CSSBI, increasing 40%. On the opposite end, Arcadia came down strong from it’s pop in March. Overall, many companies were up around 20%, indicating broad interest in synthetic biology companies from the public market.

Changes made to index

Removed AveXis, which was acquired.

You can view the index here.

Allocation as of April 7, 2018

Calvin Schmidt Synthetic Biology Index: May Update

Calvin Schmidt Synthetic Biology Index: March Update